Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd shared hopeful results in a global webcast, revealing positive data for patients with negative PD-L1 expression as part of their TACTI-003 study, presented at the ESMO Virtual Plenary. The company stressed that the information should be considered alongside its other public disclosures. Investors are advised to refer to the company’s official channels for comprehensive details and to view forward-looking statements with caution due to potential risks and uncertainties.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
